Drug Information

From a pharmacovigilance standpoint, Ramadan represents a period of systematic medication schedule disruption, altered drug pharmacokinetics, and increased vulnerability to adverse drug reactions (ADRs).

At its January 2026 meeting, PRAC adopted important new safety information concerning three distinct medicinal products: cefazolin (and cefazolin with lidocaine), erdatinib, and pegylated liposomal doxorubicin.

Chronic Kidney Disease (CKD) significantly alters the pharmacokinetics and pharmacodynamics of many drugs, making medication management a critical aspect of patient care. In the context of dialysis access procedures—such as central venous catheter insertion or arteriovenous fistula placement—drug safety becomes even more paramount. This article synthesizes key recommendations and evidence-based practices from the...

This document is a supplementary publication from the European Medicines Agency (EMA). It provides the exact legal wording that must be inserted into the official product information for medicines, based on the safety recommendations made by the Pharmacovigilance Risk Assessment Committee (PRAC) during its October 2025 meeting.

This document is a comprehensive guide published by the World Health Organization (WHO) in 2022. Its primary purpose is to provide simple, evidence-based guidance on the use of antibiotics for common infections in both adults and children. The book is designed as a practical tool to improve antibiotic prescribing globally and to combat...

In the high-stakes environment of patient care, we administer powerful medications with the intent to heal, to cure, and to save lives. Yet, for certain critical drugs, this intent rests upon a razor's edge. A single, seemingly minor error—the choice of an incorrect intravenous fluid for reconstitution—can instantly transform a lifesaving therapy into...

This WHO document is a practical guide and handbook specifically focused on the pharmacovigilance of medicines used to treat tuberculosis (TB).